MD3250208T2 - 7-Benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-onă și sărurile acesteia și utilizarea lor în terapie - Google Patents
7-Benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-onă și sărurile acesteia și utilizarea lor în terapieInfo
- Publication number
- MD3250208T2 MD3250208T2 MDE20170317T MDE20170317T MD3250208T2 MD 3250208 T2 MD3250208 T2 MD 3250208T2 MD E20170317 T MDE20170317 T MD E20170317T MD E20170317 T MDE20170317 T MD E20170317T MD 3250208 T2 MD3250208 T2 MD 3250208T2
- Authority
- MD
- Moldova
- Prior art keywords
- benzyl
- salts
- hexahydroimidazo
- pyrido
- pyrimidin
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 4
- DFULPGUTXZTYKA-UHFFFAOYSA-N 11-benzyl-7-[[4-(trifluoromethyl)phenyl]methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one Chemical compound C(C1=CC=CC=C1)N1CC=2C(N(C=3N(C=2CC1)CCN=3)CC1=CC=C(C=C1)C(F)(F)F)=O DFULPGUTXZTYKA-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9413—Dopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
Abstract
Această invenţie se referă la metode de tratament utilizând compusul (1) sau analogi ai acestuia şi săruri acceptabile farmaceutic ale acestuia. De asemenea, sunt dezvăluiţi compuşii cu formula (10) aşa cum sunt definiţi în specificaţie, şi sărurile acceptabile farmaceutic ale acestora, precum şi compoziţiile farmaceutice care le conţin. Sunt furnizate metode de tratament, cum ar fi tratamentul cancerului, care cuprind administrarea compuşilor şi a sărurilor acestora unui subiect care are nevoie de un astfel de tratament.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562109737P | 2015-01-30 | 2015-01-30 | |
US201562148844P | 2015-04-17 | 2015-04-17 | |
US201562233757P | 2015-09-28 | 2015-09-28 | |
PCT/US2016/015817 WO2016123571A1 (en) | 2015-01-30 | 2016-01-29 | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3250208T2 true MD3250208T2 (ro) | 2021-02-28 |
Family
ID=56544438
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20170317T MD3250208T2 (ro) | 2015-01-30 | 2016-01-29 | 7-Benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-onă și sărurile acesteia și utilizarea lor în terapie |
Country Status (25)
Country | Link |
---|---|
US (4) | US9845324B2 (ro) |
EP (2) | EP3805222A3 (ro) |
JP (2) | JP6802172B2 (ro) |
KR (2) | KR102618971B1 (ro) |
CN (2) | CN107427516B8 (ro) |
AU (4) | AU2016211243B2 (ro) |
BR (1) | BR112017016487B1 (ro) |
CA (3) | CA3209515A1 (ro) |
CY (1) | CY1123616T1 (ro) |
DK (1) | DK3250208T3 (ro) |
EA (1) | EA037552B1 (ro) |
ES (1) | ES2839401T3 (ro) |
HR (1) | HRP20201949T1 (ro) |
HU (1) | HUE052821T2 (ro) |
IL (4) | IL288525B (ro) |
LT (1) | LT3250208T (ro) |
MA (2) | MA41434B1 (ro) |
MD (1) | MD3250208T2 (ro) |
MX (3) | MX2017009841A (ro) |
PL (1) | PL3250208T3 (ro) |
PT (1) | PT3250208T (ro) |
RS (1) | RS61243B1 (ro) |
SG (2) | SG10201803508WA (ro) |
SI (1) | SI3250208T1 (ro) |
WO (1) | WO2016123571A1 (ro) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102618971B1 (ko) * | 2015-01-30 | 2023-12-27 | 온코슈틱스 인코포레이티드 | 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조 [1,2-a]피리도[3,4-e]피리미딘-5(1h)-온, 그것의 유사체, 및 그것의 염과 치료에서의 그것의 사용 방법 |
CN104860948B (zh) | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
SG10202108306UA (en) * | 2016-01-29 | 2021-08-30 | Oncoceutics Inc | G protein-coupled receptor (gpcr) modulation by imipridones |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
EP3496724B8 (en) * | 2016-08-12 | 2021-11-17 | Madera Therapeutics, LLC | Protein kinase regulators |
WO2018169994A1 (en) * | 2017-03-13 | 2018-09-20 | City Of Hope | m6A mRNA MODIFICATION IN CANCER TREATMENT |
EP3589745A1 (en) * | 2018-04-11 | 2020-01-08 | Chemestmed Ltd. | A method of modulating the rna methylation |
JP7364664B2 (ja) | 2019-03-26 | 2023-10-18 | 富士フイルム株式会社 | B型肝炎ウイルスタンパク質の産生を阻害する医薬組成物、b型肝炎を処置するための医薬組成物およびスクリーニング方法 |
CN116437925A (zh) * | 2020-08-06 | 2023-07-14 | 厄特沃什罗兰科技大学 | 新的依米立酮衍生物的合成及其抗癌活性的评估 |
JPWO2022071367A1 (ro) | 2020-09-30 | 2022-04-07 | ||
CN113100233B (zh) * | 2021-04-19 | 2022-02-08 | 中国农业科学院植物保护研究所 | 芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用 |
CN115448921B (zh) * | 2021-06-08 | 2023-08-01 | 四川大学 | 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途 |
CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2150062A1 (de) * | 1971-10-07 | 1973-04-12 | Boehringer Sohn Ingelheim | Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung |
US4642345A (en) | 1980-08-14 | 1987-02-10 | Mead Johnson & Company | 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones |
US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
US7635690B2 (en) | 1999-01-22 | 2009-12-22 | Emory University | HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine |
US7741285B2 (en) * | 2001-11-13 | 2010-06-22 | Genentech, Inc. | APO-2 ligand/trail formulations |
AU2003217961B2 (en) | 2002-03-08 | 2008-02-28 | Signal Pharmaceuticals, Llc | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
AU2003253186A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
WO2004082570A2 (en) | 2003-03-17 | 2004-09-30 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2) |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
EP1644536A4 (en) | 2003-07-08 | 2008-07-23 | Univ California | GENETIC MARKERS FOR RESPONSE TO ATYPIC ANTIPSYCHOTICS AND ANTIDEPRESSIVA AND METHOD FOR USE THEREOF |
DK3248600T3 (da) | 2005-02-18 | 2020-07-06 | Abraxis Bioscience Llc | Kombinationer og måder til administration af terapeutiske stoffer og kombinationsterapi |
US20080221135A1 (en) | 2005-05-13 | 2008-09-11 | Bristol-Myers Squibb Company | Combination therapy |
US8088895B2 (en) | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
WO2010033315A1 (en) | 2008-09-22 | 2010-03-25 | Amgen Inc. | Method of treatment |
AU2009324464B2 (en) | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
US9724337B2 (en) | 2009-04-21 | 2017-08-08 | University Of Kentucky Research Foundation | AG-205 for the treatment of breast cancer |
EP2571877B1 (en) | 2010-05-17 | 2018-08-15 | Boehringer Ingelheim International GmbH | 1h-imidazo[4,5-c]quinolines |
US8735386B2 (en) | 2010-07-23 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Aminopyrazoloquinazolines |
AU2012240246A1 (en) * | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
US20130102595A1 (en) * | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
ES2786033T3 (es) * | 2011-04-29 | 2020-10-08 | Penn State Res Found | Inducción del gen de TRAIL por moléculas pequeñas en células normales y tumorales como una terapia contra el cáncer |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
AU2014244117B2 (en) * | 2013-03-13 | 2018-12-20 | Oncoceutics, Inc. | Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one |
US9376437B2 (en) * | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
WO2015073072A1 (en) * | 2013-11-15 | 2015-05-21 | Oncoceutics, Inc. | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one |
RS58745B1 (sr) * | 2013-11-15 | 2019-06-28 | Oncoceutics Inc | 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-on, njegove soli i postupci za upotrebu |
CA3158795A1 (en) * | 2014-03-31 | 2015-10-08 | The Scripps Research Institute | Pharmacophore for trail induction |
KR20150114239A (ko) * | 2014-04-01 | 2015-10-12 | 제일모직주식회사 | 내열성 및 착색성이 향상된 열가소성 수지 조성물 |
KR102618971B1 (ko) | 2015-01-30 | 2023-12-27 | 온코슈틱스 인코포레이티드 | 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조 [1,2-a]피리도[3,4-e]피리미딘-5(1h)-온, 그것의 유사체, 및 그것의 염과 치료에서의 그것의 사용 방법 |
CN104860948B (zh) * | 2015-05-15 | 2017-09-26 | 南京盖特医药技术有限公司 | 咪唑并嘧啶酮类化合物及其制备方法和应用 |
-
2016
- 2016-01-29 KR KR1020177022405A patent/KR102618971B1/ko active IP Right Grant
- 2016-01-29 CA CA3209515A patent/CA3209515A1/en active Pending
- 2016-01-29 SG SG10201803508WA patent/SG10201803508WA/en unknown
- 2016-01-29 BR BR112017016487-6A patent/BR112017016487B1/pt active IP Right Grant
- 2016-01-29 ES ES16744237T patent/ES2839401T3/es active Active
- 2016-01-29 CN CN201680008476.7A patent/CN107427516B8/zh active Active
- 2016-01-29 RS RS20201566A patent/RS61243B1/sr unknown
- 2016-01-29 LT LTEP16744237.5T patent/LT3250208T/lt unknown
- 2016-01-29 WO PCT/US2016/015817 patent/WO2016123571A1/en active Application Filing
- 2016-01-29 EA EA201791727A patent/EA037552B1/ru unknown
- 2016-01-29 AU AU2016211243A patent/AU2016211243B2/en active Active
- 2016-01-29 EP EP20198062.0A patent/EP3805222A3/en active Pending
- 2016-01-29 MA MA41434A patent/MA41434B1/fr unknown
- 2016-01-29 DK DK16744237.5T patent/DK3250208T3/da active
- 2016-01-29 KR KR1020237044537A patent/KR20240005186A/ko active Search and Examination
- 2016-01-29 CA CA2975476A patent/CA2975476C/en active Active
- 2016-01-29 MA MA055402A patent/MA55402A/fr unknown
- 2016-01-29 SI SI201631003T patent/SI3250208T1/sl unknown
- 2016-01-29 HU HUE16744237A patent/HUE052821T2/hu unknown
- 2016-01-29 PT PT167442375T patent/PT3250208T/pt unknown
- 2016-01-29 JP JP2017540230A patent/JP6802172B2/ja active Active
- 2016-01-29 SG SG11201706062TA patent/SG11201706062TA/en unknown
- 2016-01-29 IL IL288525A patent/IL288525B/en unknown
- 2016-01-29 PL PL16744237T patent/PL3250208T3/pl unknown
- 2016-01-29 CA CA3209519A patent/CA3209519A1/en active Pending
- 2016-01-29 CN CN202110266214.3A patent/CN113149985A/zh active Pending
- 2016-01-29 EP EP16744237.5A patent/EP3250208B1/en active Active
- 2016-01-29 MX MX2017009841A patent/MX2017009841A/es unknown
- 2016-01-29 MD MDE20170317T patent/MD3250208T2/ro unknown
- 2016-01-29 MX MX2021001096A patent/MX2021001096A/es unknown
- 2016-01-29 IL IL295286A patent/IL295286B1/en unknown
- 2016-02-22 US US15/049,613 patent/US9845324B2/en active Active
-
2017
- 2017-07-27 IL IL253689A patent/IL253689B/en active IP Right Grant
- 2017-07-28 MX MX2023000782A patent/MX2023000782A/es unknown
- 2017-11-20 US US15/817,896 patent/US10266533B2/en active Active
-
2019
- 2019-02-27 US US16/287,195 patent/US20190194201A1/en not_active Abandoned
-
2020
- 2020-04-22 IL IL274135A patent/IL274135B/en unknown
- 2020-11-26 JP JP2020195955A patent/JP2021050209A/ja active Pending
- 2020-12-05 HR HRP20201949TT patent/HRP20201949T1/hr unknown
- 2020-12-07 CY CY20201101158T patent/CY1123616T1/el unknown
- 2020-12-07 AU AU2020286168A patent/AU2020286168B8/en active Active
-
2021
- 2021-06-24 US US17/357,008 patent/US11976068B2/en active Active
-
2022
- 2022-09-06 AU AU2022228096A patent/AU2022228096A1/en not_active Abandoned
-
2024
- 2024-05-22 AU AU2024203421A patent/AU2024203421A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3250208T2 (ro) | 7-Benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-onă și sărurile acesteia și utilizarea lor în terapie | |
EA201692095A1 (ru) | Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака | |
CY1122566T1 (el) | Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου | |
EA201890888A1 (ru) | Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53 | |
MX2017012393A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
EA202090486A3 (ru) | Соединения для лечения спинальной мышечной атрофии | |
MX2017007814A (es) | Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico. | |
MX2016009403A (es) | Compuestos heterociclicos. | |
EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
MY192354A (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
NZ709260A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
MD3288940T2 (ro) | Azabenzimidazoli și utilizarea lor ca modulatori ai receptorilor AMPA | |
PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
PH12016502353A1 (en) | Pharmaceutical composition | |
TW201613577A (en) | Pharmaceutical combinations | |
MX2021006156A (es) | Compuestos utiles en la terapia para el vih. | |
CY1120602T1 (el) | [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων | |
MD3303331T2 (ro) | Modulatori alosterici pozitivi ai receptorilor muscarinici M1 | |
EA201892311A1 (ru) | Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга | |
MD3484467T2 (ro) | Combinație de antagoniști ai receptorilor 5-HT6 puri cu inhibitori ai acetilcolinesterazei | |
PH12016501625A1 (en) | Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists | |
EA201792170A1 (ru) | Производные индола | |
EA202190165A1 (ru) | 7-БЕНЗИЛ-4-(2-МЕТИЛБЕНЗИЛ)-2,4,6,7,8,9-ГЕКСАГИДРОИМИДАЗО[1,2-a]ПИРИДО[3,4-e]ПИРИМИДИН-5(1Н)-ОН, ЕГО АНАЛОГИ И СОЛИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ В ТЕРАПИИ | |
EA201600411A1 (ru) | Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний |